Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Posted by on Apr 24th, 2024

Analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a note issued to investors on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Trevena in a report on Tuesday, April 2nd.

Check Out Our Latest Stock Analysis on TRVN

Trevena Price Performance

Shares of NASDAQ:TRVN opened at $0.39 on Monday. The company has a debt-to-equity ratio of 8.35, a current ratio of 4.66 and a quick ratio of 4.66. Trevena has a 1-year low of $0.30 and a 1-year high of $3.28. The company has a market capitalization of $7.11 million, a P/E ratio of -0.12 and a beta of 1.10. The firm’s 50 day simple moving average is $0.50 and its two-hundred day simple moving average is $0.58.

Hedge Funds Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC bought a new position in Trevena, Inc. (NASDAQ:TRVN – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned approximately 0.32% of Trevena as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 13.56% of the company’s stock.

About Trevena

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Articles

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.